Mandate

Vinge advises Dollar Financial Corp on its acquisition of Folkia

August 30, 2010

Vinge is acting as Swedish counsel to Dollar Financial Corp in connection with Dollar Financial Corp's acquisition of Folkia Group AS, a leading Scandinavian internet lending business with headquarters in Stockholm, Sweden. Dollar Financial Corp is a leading international diversified financial services company primarily serving unbanked and under-banked consumers. Folkia, which was founded in 2006, currently originates loans through both internet and SMS text cell phone technology in four countries; Sweden, Finland, Denmark, and Estonia. The completion of the acquisition is contingent upon customary closing conditions, including local regulatory approval.

The Vinge team advising Dollar Financial Corp includes corporate partner Jan Byström and corporate associates Martina Engström and Anna-Sofia Nilsson Prevell. Partner Fredrik Dahl and associate Philip Watson are providing employment benefits advice. Partner Mikael Ståhl and associates Dan Hanqvist and Adam Weissbach are providing financial services and regulatory advice.

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025